Evoke Pharma Asset Turnover 2012-2024 | EVOK

Evoke Pharma asset turnover from 2012 to 2024. Asset turnover can be defined as the amount of sales or revenues generated per dollar of assets. The asset turnover ratio is an indicator of the efficiency with which a company is deploying its assets.
Evoke Pharma Asset Turnover Historical Data
Date
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.040B 6.57
Dr Reddy's Laboratories (RDY) India $13.038B 19.39
BridgeBio Pharma (BBIO) United States $4.901B 0.00
Bausch Health Cos (BHC) Canada $2.746B 2.12
Amphastar Pharmaceuticals (AMPH) United States $1.937B 11.65
Supernus Pharmaceuticals (SUPN) United States $1.663B 0.00
Taysha Gene Therapies (TSHA) United States $0.400B 0.00
Personalis (PSNL) United States $0.200B 0.00
Assembly Biosciences (ASMB) United States $0.083B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.023B 0.00
Teligent (TLGT) United States $0.000B 0.00